foxo4 dri FOXO4-DRI Figure 5 — FOXO4-DRI alleviates
Description
Cell viability assays The cells were plated in triplicate in 96-well plates (typically 7000 senescent and 2000 non-senescent cells)
We prefer injections
Pregnant or breastfeeding individuals No safety data exists for cagrilintide use during pregnancy or breastfeeding
This can be a network of interconnected evidence previously envisaged in the implementation of the cytoprotection effects (see Figure 1)
